The US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for a Phase II study of Processa Pharmaceuticals’ VT-7208 in chronic spontaneous urticaria (CSU).  Processa is advancing VT-7208, a next-generation, CNS-penetrant, once-daily oral BTK inhibitor, across three Phase II proof-of-concept programmes, including CSU, food allergy and relapsing multiple sclerosis.  The […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!